Acute motor axonal neuropathy: an antibody-mediated attack on axolemma.

PubWeight™: 1.59‹?› | Rank: Top 4%

🔗 View Article (PMID 8871584)

Published in Ann Neurol on October 01, 1996

Authors

C Hafer-Macko1, S T Hsieh, C Y Li, T W Ho, K Sheikh, D R Cornblath, G M McKhann, A K Asbury, J W Griffin

Author Affiliations

1: Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Articles citing this

Campylobacter species and Guillain-Barré syndrome. Clin Microbiol Rev (1998) 4.39

Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. Proc Natl Acad Sci U S A (2004) 2.16

Immunoreactivity of glycoproteins isolated from human peripheral nerve and Campylobacter jejuni (O:19). J Neurosci Rural Pract (2011) 2.00

Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog Neurobiol (2010) 1.54

Dysfunction of nodes of Ranvier: a mechanism for anti-ganglioside antibody-mediated neuropathies. Exp Neurol (2011) 1.51

Comparison of Campylobacter jejuni isolates implicated in Guillain-Barré syndrome and strains that cause enteritis by a DNA microarray. Infect Immun (2004) 1.50

Sialic acids in the brain: gangliosides and polysialic acid in nervous system development, stability, disease, and regeneration. Physiol Rev (2014) 1.32

Quantifying the association between Campylobacter infection and Guillain-Barré syndrome: a systematic review. J Health Popul Nutr (2010) 1.21

Comparative genomic analysis of Campylobacter jejuni associated with Guillain-Barré and Miller Fisher syndromes: neuropathogenic and enteritis-associated isolates can share high levels of genomic similarity. BMC Genomics (2007) 1.20

Antiganglioside antibodies and their pathophysiological effects on Guillain-Barré syndrome and related disorders--a review. Glycobiology (2009) 1.19

Guillain-Barré syndrome associated with normal or exaggerated tendon reflexes. J Neurol (2011) 1.12

Biomarkers of Guillain-Barré Syndrome: Some Recent Progress, More Still to Be Explored. Mediators Inflamm (2015) 1.03

Node of Ranvier disruption as a cause of neurological diseases. ASN Neuro (2013) 1.01

Mechanisms of distal axonal degeneration in peripheral neuropathies. Neurosci Lett (2015) 1.00

Neuro-glial interactions at the nodes of Ranvier: implication in health and diseases. Front Cell Neurosci (2013) 0.94

Guillain-Barré syndrome and anti-ganglioside antibodies: a clinician-scientist's journey. Proc Jpn Acad Ser B Phys Biol Sci (2012) 0.90

Guillain-barré syndrome animal model: the first proof of molecular mimicry in human autoimmune disorder. J Biomed Biotechnol (2010) 0.90

Cerebrospinal fluid biomarkers in Guillain-Barré syndrome--where do we stand? J Neurol (2009) 0.90

Isolated absence of F waves and proximal axonal dysfunction in Guillain-Barré syndrome with antiganglioside antibodies. J Neurol Neurosurg Psychiatry (2000) 0.89

Anti-ganglioside antibodies alter presynaptic release and calcium influx. Neurobiol Dis (2007) 0.89

Anti-ganglioside antibody internalization attenuates motor nerve terminal injury in a mouse model of acute motor axonal neuropathy. J Clin Invest (2012) 0.87

Molecular mimicry: its evolution from concept to mechanism as a cause of autoimmune diseases. Monoclon Antib Immunodiagn Immunother (2014) 0.86

Axonal and perikaryal involvement in chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry (1999) 0.83

Anti-Ganglioside Antibodies Induce Nodal and Axonal Injury via Fcγ Receptor-Mediated Inflammation. J Neurosci (2015) 0.82

Antibody responses to peptides of peripheral nerve myelin proteins P0 and P2 in patients with inflammatory demyelinating neuropathy. J Neurol Neurosurg Psychiatry (2006) 0.81

Neuroinflammation in the peripheral nerve: Cause, modulator, or bystander in peripheral neuropathies? Glia (2015) 0.80

An update on pathobiologic roles of anti-glycan antibodies in Guillain-Barré syndrome. F1000 Biol Rep (2010) 0.80

Progress in inflammatory neuropathy -the legacy of Dr Jack Griffin. Nat Rev Neurol (2015) 0.79

More severe manifestations and poorer short-term prognosis of ganglioside-associated Guillain-Barré syndrome in Northeast China. PLoS One (2014) 0.79

Systematic reviews of treatment for inflammatory demyelinating neuropathy. J Anat (2002) 0.79

Gene expression profiling in multiple sclerosis brain. Neurobiol Dis (2010) 0.79

Prediction of Functional Outcome in Axonal Guillain-Barre Syndrome. Ann Rehabil Med (2016) 0.79

Elevated levels of S100B, tau and pNFH in cerebrospinal fluid are correlated with subtypes of Guillain-Barré syndrome. Neurol Sci (2012) 0.79

Action mechanism of corticosteroids to aggravate Guillain-Barré syndrome. Sci Rep (2015) 0.78

Autoantobodies activate small GTPase RhoA to modulate neurite outgrowth. Small GTPases (2011) 0.77

Paranodal permeability in "myelin mutants". Glia (2011) 0.77

Circulating memory T follicular helper subsets, Tfh2 and Tfh17, participate in the pathogenesis of Guillain-Barré syndrome. Sci Rep (2016) 0.76

Guillain-Barré syndrome: a century of progress. Nat Rev Neurol (2016) 0.76

Identification of gene networks and pathways associated with Guillain-Barré syndrome. PLoS One (2012) 0.76

A variant of multifocal motor neuropathy with acute, generalised presentation and persistent conduction blocks. J Neurol Neurosurg Psychiatry (2003) 0.76

Sialylated intravenous immunoglobulin suppress anti-ganglioside antibody mediated nerve injury. Exp Neurol (2016) 0.76

C1q-targeted inhibition of the classical complement pathway prevents injury in a novel mouse model of acute motor axonal neuropathy. Acta Neuropathol Commun (2016) 0.75

Articles by these authors

Cytochemical identification of monocytes and granulocytes. Am J Clin Pathol (1971) 20.35

Adhesive force of a single gecko foot-hair. Nature (2000) 10.56

Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol (1990) 8.54

Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology (2007) 8.08

Esterases in human leukocytes. J Histochem Cytochem (1973) 7.37

Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology (2011) 7.09

Occupational exposure to inorganic mercury vapour and reproductive outcomes. Occup Med (Lond) (1998) 5.33

Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature (2001) 5.07

Research methodology in occupational medicine. Occup Med (Lond) (1998) 4.88

Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res (2001) 4.87

The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. Medicine (Baltimore) (1969) 4.72

Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology (2005) 3.67

Benzene and the dose-related incidence of hematologic neoplasms in China. Chinese Academy of Preventive Medicine--National Cancer Institute Benzene Study Group. J Natl Cancer Inst (1997) 3.61

The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology (2003) 3.60

Epidermal nerve fiber density: normative reference range and diagnostic efficiency. Arch Neurol (1998) 3.39

Quantitative sensory testing: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology (2003) 3.23

EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy. Eur J Neurol (2005) 3.17

European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Eur J Neurol (2010) 3.10

Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia (2008) 3.04

Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China. Lancet (1991) 2.87

Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2003) 2.76

Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol (1990) 2.66

European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol (2010) 2.64

Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain (1995) 2.61

Diagnostic considerations in Guillain-Barré syndrome. Ann Neurol (1981) 2.53

Cytokine expression in the brain during the acquired immunodeficiency syndrome. Ann Neurol (1992) 2.52

Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol (1998) 2.47

Investigating non-response bias in mail surveys. J Epidemiol Community Health (1981) 2.43

Myelin-associated glycoprotein is a myelin signal that modulates the caliber of myelinated axons. J Neurosci (1998) 2.43

Increased expression of neurofilament subunit NF-L produces morphological alterations that resemble the pathology of human motor neuron disease. Cell (1993) 2.40

Myeloma with involvement of the serous cavities. Cytologic and immunochemical diagnosis and literature review. Acta Cytol (1990) 2.36

Neurofilament gene expression: a major determinant of axonal caliber. Proc Natl Acad Sci U S A (1987) 2.36

Multifocal motor neuropathy: response to human immune globulin. Ann Neurol (1993) 2.32

Patterns of Guillain-Barre syndrome in children: results from a Mexican population. Neurology (2007) 2.32

Diffusion- and perfusion-weighted brain magnetic resonance imaging in patients with neurologic complications after cardiac surgery. Arch Neurol (2001) 2.30

Guillain-Barré syndrome in northern China. The spectrum of neuropathological changes in clinically defined cases. Brain (1995) 2.29

Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol (1993) 2.23

Practice Parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology (2008) 2.19

Adrenomyeloneuropathy: a probable variant of adrenoleukodystrophy. I. Clinical and endocrinologic aspects. Neurology (1977) 2.19

Accuracy of clinical criteria for AD in the Honolulu-Asia Aging Study, a population-based study. Neurology (2001) 2.15

Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection. Neurology (1997) 2.15

Practice Parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology (2008) 2.15

Repeatability and validity of a modified activities of daily living (ADL) index in studies of chronic disability. Int Rehabil Med (1979) 2.14

The role of Schwann cells in the formation of "onion bulbs" found in chronic neuropathies. J Neuropathol Exp Neurol (1967) 2.13

Acute megakaryocytic leukemia (M7) in children. Mayo Clin Proc (1989) 2.13

Measurement of the intensity of cell surface antigen expression in B-cell chronic lymphocytic leukemia. Am J Clin Pathol (1994) 2.13

A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol (1988) 2.12

Intracerebral cytokine messenger RNA expression in acquired immunodeficiency syndrome dementia. Ann Neurol (1993) 2.09

Histochemical characterization of cellular and structural elements of the human spleen. J Histochem Cytochem (1972) 2.08

Inflammatory demyelinating peripheral neuropathies associated with human T-cell lymphotropic virus type III infection. Ann Neurol (1987) 2.05

Control of axonal caliber by neurofilament transport. J Cell Biol (1984) 2.03

Dynamics of geckos running vertically. J Exp Biol (2006) 2.00

Slow axonal transport of neurofilament proteins: impairment of beta,beta'-iminodipropionitrile administration. Science (1978) 2.00

Glue-sniffing neuropathy. Arch Neurol (1975) 1.99

Cellular autofluorescence--is it due to flavins? J Histochem Cytochem (1979) 1.99

Schwann cells express motor and sensory phenotypes that regulate axon regeneration. J Neurosci (2006) 1.97

Oculomotor palsy in diabetes mellitus: a clinico-pathological study. Brain (1970) 1.96

Mice lacking complex gangliosides develop Wallerian degeneration and myelination defects. Proc Natl Acad Sci U S A (1999) 1.95

Cutaneous innervation in sensory neuropathies: evaluation by skin biopsy. Neurology (1995) 1.95

Epidermal nerve fiber density and sural nerve morphometry in peripheral neuropathies. Neurology (1999) 1.93

Ataxic sensory neuropathy and dorsal root ganglionitis associated with Sjögren's syndrome. Ann Neurol (1990) 1.92

Giant axonal neuropathy--a unique case with segmental neurofilamentous masses. Acta Neuropathol (1972) 1.91

Axotomy-induced axonal degeneration is mediated by calcium influx through ion-specific channels. J Neurosci (1995) 1.88

Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann Neurol (1996) 1.85

Remedial therapy after stroke: a randomised controlled trial. Br Med J (Clin Res Ed) (1981) 1.84

Guillain-Barré syndrome and Hodgkin's disease: three cases with immunological studies. Ann Neurol (1977) 1.84

Cognitive changes 5 years after coronary artery bypass grafting: is there evidence of late decline? Arch Neurol (2001) 1.83

True T-cell chronic lymphocytic leukemia: a morphologic and immunophenotypic study of 25 cases. Blood (1995) 1.81

HIV-associated disease of the nervous system: review of nomenclature and proposal for neuropathology-based terminology. Brain Pathol (1991) 1.81

The clinical correlates of high-titer IgG anti-GM1 antibodies. Ann Neurol (1994) 1.79